ACT VENLAFAXINE XR 75 MG
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) : 75 MG · DIN 02304325 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is ACT VENLAFAXINE XR?
ACT VENLAFAXINE XR 75 MG contains VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02304325, held by TEVA CANADA LIMITED, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT VENLAFAXINE XR used for?
Symptomatic relief of Major depressive disorder, Generalized anxiety disorder (GAD), Social anxiety disorder (social phobia), and Panic disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02304325 |
|---|---|
| Brand name | ACT VENLAFAXINE XR |
| Generic / active ingredient | VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) : 75 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 75 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX16 VENLAFAXINE |
| AHFS class | 28:16.04.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Mar-2019 |
| Original market date | 2008-02-13 00:00:00 |
How is it administered?
Administer once daily with food (morning or evening). MDD/GAD/Social Anxiety: Start 37.5-75 mg/day. Panic Disorder: Start 37.5 mg/day for 7 days. Max dose 225 mg/day. Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (section 11 is listed in TOC but content is missing).
How is it supplied?
Available in strengths of 37.5 mg, 75 mg, and 150 mg. (Specific container sizes like bottles not provided in text snippet).
Contraindications
Hypersensitivity to venlafaxine or any ingredient; concurrent use of MAOIs or within 14 days of discontinuing MAOIs.
Warnings and precautions
Serious risk of self-harm and suicidal behavior. Risk of Serotonin Syndrome, Neuroleptic Malignant Syndrome, and discontinuation symptoms. Monitor for clinical worsening.
Is VENLAFAXINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX16 VENLAFAXINE. 36 of 90 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT VENLAFAXINE XR | 150 MG | CAPSULE (EXTENDED RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02304333 |
| ACT VENLAFAXINE XR | 37.5 MG | CAPSULE (EXTENDED RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02304317 |
| AURO-VENLAFAXINE XR | 150 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02452855 |
| AURO-VENLAFAXINE XR | 37.5 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02452839 |
| AURO-VENLAFAXINE XR | 75 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | DIN 02452847 |
| EFFEXOR XR | 150 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02237282 |
| EFFEXOR XR | 37.5 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02237279 |
| EFFEXOR XR | 75 MG | CAPSULE (EXTENDED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02237280 |
| M-VENLAFAXINE XR | 150 MG | CAPSULE (EXTENDED RELEASE) | MANTRA PHARMA INC | MARKETED | DIN 02471302 |
| M-VENLAFAXINE XR | 37.5 MG | CAPSULE (EXTENDED RELEASE) | MANTRA PHARMA INC | MARKETED | DIN 02471280 |
Who else supplies VENLAFAXINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VENLAFAXINE appears in 546 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.